Virginia State Pharmacy Board v. Virginia Citizens Consumer Council

Nephron Announces New President of 503B Outsourcing Facility

Retrieved on: 
Thursday, June 8, 2023
University, The Washington Post, Associated Press, Press, Pharmacy, Doctor of Pharmacy, Mass General Brigham, Education, IV, The Wall Street Journal, NPR, American Society of Health-System Pharmacists, Virginia State Pharmacy Board v. Virginia Citizens Consumer Council, Medical school, Multimedia, NBC, Harvard Medical School, Hospital, Bloomberg, NBC Nightly News, Mass, Council, Nephron, Northeastern University, ASHP, Massachusetts General Hospital, Society, Nursing, Management, News

WEST COLUMBIA, S.C., June 8, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced Christopher Fortier, PharmD, FASHP, CPEL, will join as President of its 503B Outsourcing Facility.

Key Points: 
  • WEST COLUMBIA, S.C., June 8, 2023 /PRNewswire/ -- Nephron Pharmaceuticals Corporation today announced Christopher Fortier, PharmD, FASHP, CPEL, will join as President of its 503B Outsourcing Facility.
  • "That combination will be an invaluable asset to the Nephron team."
  • Prior to joining Nephron, Fortier was the Chief Pharmacy Officer at Massachusetts General Hospital in Boston.
  • The company also operates an industry-leading 503B Outsourcing Facility division which produces pre-filled sterile syringes, luer-lock vials, IV bottles and IV bags for hospitals across America, in an effort to alleviate drug shortage needs.

New Report Shows Pharmacy Benefit Managers Are Increasing Costs for Patients and the Health Care System

Retrieved on: 
Thursday, December 2, 2021
Insurance, Professional Services, Public Policy, Government, Healthcare Reform, Biotechnology, General Health, Pharmaceutical, Health, Public Policy, Other Policy Issues, Patient, PBM, Policy, Government, Disclosure, Health, Competition law, Virginia State Pharmacy Board v. Virginia Citizens Consumer Council, Federal Trade Commission, Solution, Revenue, Elijah Cummings Lower Drug Costs Now Act, Research, National Consumers League, National Alliance, Medicine, Pharmacy, Pharmacist, Pharmacy benefit management, Growth, Health insurance, Pharmaceutical industry, Healthcare

It concludes by considering the impact of PBM incentive structures and the need to include PBM reforms in prescription drug policy discussions.

Key Points: 
  • It concludes by considering the impact of PBM incentive structures and the need to include PBM reforms in prescription drug policy discussions.
  • Gross profit from PBM-owned mail order and specialty pharmacies increased by more than 13% from $8.9 billion in 2017 to $10.1 billion in 2019.
  • PBMs have been remarkably adept at creating clever ways to divert prescription drug savings away from health plan sponsors and patients and into their own growing profit.
  • Excess complexity and information asymmetry in the market prevent payers and patients from properly evaluating PBM decisions or drug costs.